{
  "metadata": {
    "case_id": 56,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T17:11:37.226159",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/56_NCT03275350.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/56_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.78,
          0.1
        ],
        [
          0.2,
          0.94
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "label": "XR-NTX",
            "type": "ACTIVE_COMPARATOR",
            "description": "Extended-release naltrexone",
            "interventionNames": [
              "Drug: Naltrexone Injectable Suspension"
            ]
          },
          "pred_item": {
            "label": "Extended-Release Naltrexone (XR-NTX)",
            "type": "EXPERIMENTAL",
            "description": "Participants with HIV and opioid use disorder randomized to receive HIV clinic-based extended-release naltrexone (XR-NTX), which requires complete cessation of opioid use prior to induction. XR-NTX is a deep muscle injection that lasts 28 days.",
            "interventionNames": [
              "DRUG: Extended-Release Naltrexone (XR-NTX)",
              "BEHAVIORAL: Opioid withdrawal management",
              "BEHAVIORAL: Supportive counseling"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "label": "TAU",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment as usual",
            "interventionNames": [
              "Other: Treatment as usual"
            ]
          },
          "pred_item": {
            "label": "Treatment-as-Usual (Opioid Agonist Therapy)",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants with HIV and opioid use disorder randomized to treatment-as-usual, which includes opioid agonist therapy with buprenorphine or methadone.",
            "interventionNames": [
              "DRUG: Buprenorphine",
              "DRUG: Methadone"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 5,
      "similarity_matrix": [
        [
          0.98,
          0.3,
          0.4,
          0.36,
          0.15
        ],
        [
          0.25,
          0.4,
          0.72,
          0.4,
          0.4
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Naltrexone Injectable Suspension",
            "description": "Six monthly injections of extended-release naltrexone",
            "armGroupLabels": [
              "XR-NTX"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Extended-Release Naltrexone (XR-NTX)",
            "description": "A deep intramuscular injection of extended-release naltrexone administered once every 28 days. An opioid antagonist that blocks opioid receptors. Requires complete opioid abstinence for several days prior to first injection to avoid precipitated withdrawal.",
            "armGroupLabels": [
              "Extended-Release Naltrexone (XR-NTX)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.72,
          "status": "matched",
          "ref_item": {
            "type": "OTHER",
            "name": "Treatment as usual",
            "description": "Standard treatment for opioid use disorder provided at each HIV clinic",
            "armGroupLabels": [
              "TAU"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Methadone",
            "description": "An opioid full agonist used for medication-assisted treatment of opioid use disorder. Requires daily dosing at specialized treatment programs.",
            "armGroupLabels": [
              "Treatment-as-Usual (Opioid Agonist Therapy)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.05
        ],
        [
          0.08
        ],
        [
          0.05
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed",
            "description": "HIV-1 RNA \\<200 copies/ml",
            "timeFrame": "12 weeks and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.08,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With HIV Viral Suppression, Complete Case",
            "description": "HIV-1 RNA \\<200 copies/ml",
            "timeFrame": "12 weeks and 24 weeks"
          },
          "pred_item": {
            "measure": "Successful completion of XR-NTX induction",
            "description": "Receipt of first XR-NTX injection following opioid withdrawal and meeting opioid-free requirements",
            "timeFrame": "At induction (following withdrawal period, typically 7-14 days)"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With HIV Viral Suppression, Per-protocol",
            "description": "HIV-1 RNA \\<200 copies/ml",
            "timeFrame": "12 weeks and 24 weeks"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 10,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.06,
          0.03
        ],
        [
          0.06,
          0.02
        ],
        [
          0.05,
          0.03
        ],
        [
          0.08,
          0.02
        ],
        [
          0.06,
          0.08
        ],
        [
          0.1,
          0.05
        ],
        [
          0.08,
          0.02
        ],
        [
          0.08,
          0.08
        ],
        [
          0.18,
          0.05
        ],
        [
          0.08,
          0.18
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Veterans Aging Cohort Study (VACS) Index",
            "description": "Absolute value of participant VACS Index at baseline and 24 weeks\n\nVeterans Aging Cohort Study Index Minimum value: 0 Maximum value: 164 A higher score means a worse outcome.",
            "timeFrame": "Baseline and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "CD4 Count",
            "description": "Cluster of Differentiation 4\n\nAbsolute value of CD4 count at baseline and 24 weeks.",
            "timeFrame": "Baseline and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Engagement in HIV Care: Antiretroviral Therapy Prescribed",
            "description": "Absolute value of participants prescribed ART at baseline and within 24 weeks following randomization. Each individual can be scored 0 (not prescribed ART) or 1 (prescribed ART) at both baseline and follow-up, after which his or her outcome score will be the follow-up score minus the baseline score. Outcomes will be analyzed via rank-based methods such as Wilcoxon rank-sum tests.",
            "timeFrame": "Baseline and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Engagement in HIV Care: 100% Antiretroviral Therapy Adherence",
            "description": "Number of participants taking 100% of prescribed ART doses in the past month at 24 weeks for those prescribed ART at any point during the 24 week trial (proportion; self-reported medication adherence measure). Chi-squared test comparing proportion to treatment assignment, for those prescribed ART.",
            "timeFrame": "24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With at Least 1 HIV Care Visit in Past 12 Weeks",
            "description": "At least 1 HIV care visit in past 12 weeks",
            "timeFrame": "24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 5,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants Who Had Unprotected Sex in Past 30 Days",
            "description": "Past 30 day unprotected sex, as measured by the Risk Assessment Battery at baseline and week 24 (binary; self-report).",
            "timeFrame": "Baseline and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 6,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Multiple Sex Partners in Past 30 Days",
            "description": "Past 30 day multiple sex partners, as measured by the Risk Assessment Battery at baseline and week 24 (binary; self-report).",
            "timeFrame": "Baseline and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 7,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Engagement in HIV Care: Quality of Life",
            "description": "Past 30 day health-related quality of life as measured by the EQ-5D questionnaire at baseline and week 24.\n\nMinimum value: 0 Maximum value: 100 Higher scores mean a better outcome",
            "timeFrame": "Baseline and 24 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 8,
          "pred_idx": 0,
          "score": 0.18,
          "status": "matched",
          "ref_item": {
            "measure": "Average Number of Self-Reported Days of Opioid Use in Last 30 Days",
            "description": "Average number of days of opioid use between baseline and 24 weeks, measured by the Timeline Follow-Back (count; self-report), will be used to compare opioid use by treatment group. Confirmatory analysis will assess opioid use by the average number of days of opioid use in the last 30 days of the study (by Addiction Severity Index-lite; count; self-report) and the number of monthly urine drug screen (UDS) negative for opioids between baseline and 24 weeks (count; laboratory data).",
            "timeFrame": "Between baseline and 24 weeks"
          },
          "pred_item": {
            "measure": "Patient-reported experiences with XR-NTX induction process",
            "description": "Qualitative themes identified through semi-structured interviews regarding facilitators and barriers to XR-NTX induction, including motivation, withdrawal experience, support systems, and treatment preferences",
            "timeFrame": "Interviews conducted between July 2018 and November 2019 during or after induction attempts"
          }
        },
        {
          "ref_idx": 9,
          "pred_idx": 1,
          "score": 0.18,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants Who Test Positive for Opioids at 24 Weeks",
            "description": "Number and percent of participants with UDS positive for opioids at 24 weeks.",
            "timeFrame": "24 weeks"
          },
          "pred_item": {
            "measure": "Reasons for unsuccessful XR-NTX induction",
            "description": "Qualitative themes identified through interviews regarding barriers preventing completion of XR-NTX induction, including withdrawal concerns, ambivalence about stopping opioids, concerns about XR-NTX effects, and preferences for other medications",
            "timeFrame": "Interviews conducted between July 2018 and November 2019 following unsuccessful induction attempts"
          }
        }
      ]
    }
  ]
}